News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Business
Deals
NovaBay Pharmaceuticals, Inc. (formerly known as NovaCal Pharmaceuticals, Inc.) Sees IPO of 5 Million Shares at $4-$6 Each
August 10, 2007
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Aug 10 (Reuters) - Novabay Pharmaceuticals Inc. on Friday filed for an initial public offering of 5 million shares at an estimated price of $4 to $6 per share.
Twitter
LinkedIn
Facebook
Email
Print
IPO
MORE ON THIS TOPIC
Psychedelics
Lilly makes up to $3.8B psychedelics play in AtaiBeckley takeover
July 16, 2026
·
2 min read
·
Tristan Manalac
IPO
Braveheart, Attovia, Vogenx keep IPOs ballooning with plans to compete in cardiometabolic, immuno
July 16, 2026
·
4 min read
·
Tristan Manalac
Antibody-drug conjugate
Pfizer scraps Seagen-developed ADC for solid tumors
July 15, 2026
·
1 min read
·
Gabrielle Masson
Podcast
Biogen validates anti-tau approach at AAIC, psychedelics full speed ahead, ATTR-CM shakeup
July 15, 2026
·
1 min read
·
Jef Akst
